COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00117702
Recruitment Status : Terminated (safety reasons)
First Posted : July 8, 2005
Last Update Posted : June 18, 2009
Information provided by:
Technische Universität Dresden

Brief Summary:
The purpose of this pilot study is to provide preliminary data about the efficacy and the safety of the combination of tacrolimus with everolimus in the prophylaxis of the graft-versus-host-disease (GvHD) in patients after allogeneic stem cell transplantation.

Condition or disease Intervention/treatment Phase
Graft vs Host Disease Drug: Tacrolimus Drug: Everolimus Phase 2 Phase 3

Detailed Description:

The allogeneic stem cell transplantation is a successful therapeutic approach in the treatment of a number of hematologic diseases. Nevertheless, it is associated with substantial risks and complications. A major life-threatening complication that occurs in the post transplantation period is the graft versus host disease, especially its severe forms (Grade III and Grade IV). For this reason, a combined immunosuppressive therapy is standard in patients after a stem cell transplantation. In this regard, the combination between cyclosporin A and methotrexate in the prevention of GvHD has been particularly successful. However, the incidence rate of GvHD and consequent mortality are still fairly high. Besides, the therapy itself is accompanied by serious side effects. Therefore, there is a need for a more efficient, less toxic, combined immunosuppressive therapy. The purpose of this pilot study is to test a new combination of immunosuppressives (tacrolimus and everolimus) for the prevention of GvHD after an allogeneic stem cell transplantation. Tacrolimus is a macrolide immunosuppressant that acts as a calcineurin inhibitor, thereby preventing the activation and proliferation of the T-lymphocytes. Everolimus is a semisynthetic macrocyclic lactone that inhibits the activity of a key protein involved in the regulation of the cell cycle, the so called m-TOR protein. Both medicaments act complementary and potently inhibit the proliferation of immune cells. Previous studies have shown that the combination of tacrolimus with everolimus decreases significantly the rejection rate after solid organ transplantation and this combination is generally well tolerated.

This study is designed as a prospective, single-center, non-randomized, open-label non-controlled pilot study. Study related visits are scheduled to take place at regular time intervals and the patients will be followed up to one year after the stem cell transplantation. The study is designed and will be conducted in accordance with the ICH-GCP guidelines and the respective national and international laws.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prophylaxis of the Graft-Versus-Host-Disease in Patients After Allogeneic Stem Cell Transplantation With a Combination of Tacrolimus and Everolimus
Study Start Date : October 2005
Actual Primary Completion Date : May 2008
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: Tacrolimus
    day 0-100, then taper
    Other Name: Prograf
  • Drug: Everolimus
    day 0-56
    Other Name: Certican

Primary Outcome Measures :
  1. Incidence of acute GvHD grade III and IV within the first 100 days after the stem cell transplantation [ Time Frame: first 100 days ]

Secondary Outcome Measures :
  1. Safety (evaluated after Common Terminology Criteria for Adverse Events [CTCAE] v 3.0) [ Time Frame: within 100 days after Tx ]
  2. Hypersensitivity reactions [ Time Frame: within 56 days after Tx ]
  3. Thrombotic thrombocytopenic purpura [ Time Frame: within 56 days after Tx ]
  4. Hyperlipidemia [ Time Frame: within 56 days after Tx ]
  5. Total and relapse-free survival rate one year after the stem cell transplantation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female patients between 18 and 70 years of age
  • Planned allogeneic stem cell transplantation either from a related or an unrelated donor
  • Written informed consent

Exclusion Criteria:

  • Previous stem cell transplantation
  • Use of antibody Campath (anti CD-52) or ATG during the conditioning
  • In vitro T-cell depleted graft
  • Known hypersensitivity to everolimus or other constituents of the study medication
  • Symptomatic infectious disease
  • Hepatic disease (ASAT > 2 x ULN)
  • Renal insufficiency (creatinine > 2 x ULN)
  • HIV infection
  • Life expectancy < 3 months
  • Severe lung disease (FEV1 < 50% of the normal value)
  • Severe psychiatric disorder
  • Subjects unlikely to comply with the requirements of the protocol
  • Known or current alcohol, medication or drug abuse
  • Pregnancy or lactation
  • Women of child-bearing potential without reliable contraception unless they meet the following criteria: postmenopausal (12 months of natural amenorrhea);postoperation status (6 weeks after surgical bilateral oophorectomy with or without hysterectomy);use of highly effective birth control method (defined as one which results in a low failure rate i.e. less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomized partner)
  • Men that do not use one of the following methods for prevention of conception:sexual abstinence; condom; vasectomy
  • Participation of the subject in another clinical trial within the last 4 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00117702

Layout table for location information
Medizinische Klinik und Poliklinik I, University Clinic Carl Gustav Carus
Dresden, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Layout table for investigator information
Principal Investigator: Uwe Platzbecker, MD University Clinic Carl Gustav Carus Dresden

Layout table for additonal information
Responsible Party: TUD, Technical University Dresden Identifier: NCT00117702    
Other Study ID Numbers: 30
2005-000161-19 (EudraCT Nr.)
First Posted: July 8, 2005    Key Record Dates
Last Update Posted: June 18, 2009
Last Verified: June 2009
Keywords provided by Technische Universität Dresden:
Stem cell transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents